Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | CCR8 | P51685 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608528 | 0.95 | ALDH1A1 (0.76) | ALDH1A1CCR8KDM4EMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7438287 | 0.93 | ALDH1A1 (0.74) | ALDH1A1CCR8KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1946258 | 0.90 | L3MBTL1 (0.86) | L3MBTL1ATMALDH1A1KDM4ESMN1; SMN2 | |
| Bromide SCHEMBL10462008 | 0.89 | L3MBTL1 (0.84) | L3MBTL1ATMALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4300326 | 0.87 | L3MBTL1 (0.67) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL1545229 | 0.87 | L3MBTL1 (0.74) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL8263564 | 0.87 | L3MBTL1 (0.74) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL14022760 | 0.87 | L3MBTL1 (0.74) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL8791924 | 0.85 | CCR8 (0.81) | L3MBTL1ATMALDH1A1CCR8KDM4E | |
| SCHEMBL4693375 | 0.84 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1CCR8KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | L3MBTL1 2014/4885ATM 3805/4885ALDH1A1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.